No results for ‘’
Dr Reddys Laboratories Ltd
₹1268.50
(0.56%)
Sat, 13 Jun 2026, 10:56 am
Health Technology
Pharmaceuticals: Major
24.5KDr Reddys Laboratories PB Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 74.48 | 12.02 | 22.82 | 0 | 61.71 | 25.23 | 20.98 | 17.94 | 20.32 | 26.88 | 25.94 | 36.52 | 35.29 | 24.53 | 26.55 | 43.57 | 30.39 | 17.06 | 18.43 | 16.88 |
| Price to book ratio | 5.27 | 3.06 | 2.21 | 2.33 | 5.71 | 6.03 | 5.19 | 4.12 | 4.80 | 5.34 | 4.03 | 3.52 | 2.73 | 3.28 | 3.33 | 4.32 | 3.75 | 3.33 | 3.66 | 2.86 |
| Price to sales ratio | 4.62 | 1.78 | 2 | 1.20 | 3.08 | 3.73 | 3.09 | 2.59 | 3.31 | 4.02 | 3.36 | 3.12 | 2.44 | 3 | 2.97 | 3.96 | 3.34 | 3.13 | 3.68 | 2.93 |
| Price to cash flow ratio | 94.24 | 10.06 | 20.72 | 15.65 | 11.77 | 35.84 | 19.47 | 23.33 | 22.67 | 24.08 | 12.48 | 20.72 | 20.23 | 16.54 | 17.70 | 21.09 | 25.91 | 13.30 | 22.83 | 20.60 |
| Enterprise value | 13064Cr | 12242Cr | 11221Cr | 9713Cr | 22512Cr | 29552Cr | 31333Cr | 31517Cr | 44777Cr | 59879Cr | 51257Cr | 47041Cr | 37572Cr | 47467Cr | 51406Cr | 74675Cr | 70563Cr | 72064Cr | 96466Cr | 94698Cr |
| Enterprise value to EBITDA ratio | 40.69 | 7.39 | 13.62 | 6.66 | 15.64 | 18.87 | 13.20 | 12.59 | 14.34 | 17.62 | 13.12 | 19.47 | 16.41 | 14.94 | 12.50 | 16.66 | 15.24 | 11.11 | 12.26 | 10.94 |
| Debt to equity ratio | 1.51 | 0.62 | 0.44 | 0.57 | 0.39 | 0.51 | 0.56 | 0.51 | 0.49 | 0.39 | 0.26 | 0.40 | 0.40 | 0.27 | 0.14 | 0.18 | 0.18 | 0.06 | 0.07 | 0.14 |
| Return on equity % | 7.32 | 31.85 | 10.32 | -22.86 | 9.63 | 26.36 | 27.58 | 25.77 | 26.26 | 21.95 | 16.70 | 9.54 | 7.83 | 14.10 | 13.21 | 10.51 | 12.96 | 21.38 | 21.77 | 18.42 |
Dr Reddys Laboratories Ltd Price to Book Ratio
The Dr Reddys Laboratories Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Dr Reddys Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Dr Reddys Laboratories Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Dr Reddys Laboratories Ltd (NSE: DRREDDY, BSE: 500124) is currently trading at ₹1268.50, with a market capitalization of ₹106429.04Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Dr Reddys Laboratories Ltd Price to Book Ratio is essential for fundamental analysis.
Dr Reddys Laboratories Ltd Price to Book Ratio Current Value
The current Dr Reddys Laboratories Ltd Price to Book Ratio stands at 2.86.
The Dr Reddys Laboratories Ltd Price to Book Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Dr Reddys Laboratories Ltd Price to Book Ratio Historical Trend
The Dr Reddys Laboratories Ltd Price to Book Ratio has shown the following historical trend:
- 2024: 2.86
- 2023: 3.66
- 2022: 3.33
- 2021: 3.75
- 2020: 4.32
The decline in Dr Reddys Laboratories Ltd Price to Book Ratio indicates improving financial efficiency or better earnings growth.
What Dr Reddys Laboratories Ltd Price to Book Ratio Indicates for Investors
The Dr Reddys Laboratories Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
Dr Reddys Laboratories Ltd Price to Book Ratio Analysis Summary
The Dr Reddys Laboratories Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Dr Reddys Laboratories Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Dr Reddys Laboratories Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.